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Summary
Background Beta-blockers remain one of the most frequently prescribed antihypertensive drug classes. The aim 
of the analysis was to evaluate characteristics of patients treated with beta-blockers and factors associated with the 
treatment of beta-blockers.
Material and methods We analysed the data from the large cross-sectional study evaluating 12,375 patients treated 
for hypertension for at least one year 
Results Overall, 7080 patients (57.2% of the whole group) were treated with beta-blockers. The rate of use of be-
ta-blockers was higher in patients with diabetes (62.9 vs 55.6%), coronary artery disease (72.2 vs 46.4%), previous 
myocardial infarction (82.3 vs 54.1%), heart failure (73.1 vs 53.3%) and arrhythmias (73.1 vs 51.1%) than in pa-
tients without those conditions (all comparisons p < 0.001). Beta-blockers were used less frequently among patients 
with asthma/COPD than without asthma/COPD (54.0 vs 58.0%; p = 0.017). In patients aged 40 years and less, 
the compelling indications for these agents were found only in 21.7% of patients. In patients aged 40–65 years, 
none of compelling indications was found in 41.3% of patients. In patients 65 years or more, the most frequent 
compelling indications were coronary artery disease, previous myocardial infarction and heart failure, which were 
present in 70.1% of patients.
Conclusions High utilization rate of beta-blockers in patients with hypertension, only second to renin-angiotensin 
blockers, has been shown. In middle age and, especially, in older patients it might reflect high cardiovascular burden 
of those patients, including coexistence of established cardiac disease. In younger patients beta-blockers are used 
more frequently with none of the compelling indications present.
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Background
In the European Society of Hypertension/European 
Society of Cardiology (ESH/ESC) 2013 guidelines 
as well as in the guidelines of the Polish Society of 
Hypertension 2015, beta-blockers were maintained 
as a possible choice for antihypertensive treatment 
and were listed among five major antihypertensive 
drug classes [1–3]. However, some meta-analyses 
have reported that beta-blocker may be inferior to 
some other classes for the reduction of total mortality 
and cardiovascular events. Based on those data, some 
international guidelines did not include beta-block-
ers to the first-line antihypertensive treatment [4–6].
Despite those controversies, recent surveys have 
shown that beta-blockers remain one of the most 
frequently used groups of antihypertensive drugs, 
second or third to the most popular renin-angioten-
sin system blockers. The rate of use of beta-blockers 
remained stable or even increased in surveys evalu-
ating changes in the rate of use of antihypertensive 
medications over past decade [7–10].
The Pol-Fokus study aimed to evaluate character-
istics of hypertensive patients in Poland and factors 
related to blood pressure (BP) control in a large 
sample of hypertensive patients treated for at least 
one year under the care of general practitioners (GPs) 
and specialists (cardiologists and hypertension spe-
cialists) all over Poland [11]. The aim of the present-
ed analysis was to present clinical characteristics of 
hypertensive patients treated with beta blockers. We 
also analysed the prevalence of beta-blockers use in 
different subgroups of patients in which this class 
of antihypertensive drugs should be preferred and 
considered.
Material and methods
The methodology of the Pol-Fokus study was already 
published [11]. In summary, Pol-Fokus was a large, 
observational, cross-sectional survey of hypertensive 
subjects followed up by GPs, cardiologists and hy-
pertension specialists throughout the Polish territory. 
The study was approved by the Ethics Committee of 
the Jagiellonian University, in Krakow, Poland and 
all participants provided informed consent. Nine 
hundred and seventy-eight GPs and 286 specialists 
(cardiology or hypertensiology) from all provinces 
in Poland participated in the Pol-Fokus study. The 
methods of selection of this group has been already 
described in details [11].
The Pol-Fokus study included hypertensive pa-
tients meeting the following criteria: age 18 years 
or more, hypertension treated for at least one year, 
with at least one visit to the doctor, participating 
in the study over the last year. They had to be free 
from any acute disease in the preceding 4 weeks and 
free from known secondary causes of hypertension. 
After discarding data from doctors who did not 
achieve the specific quota or who provided incom-
plete questionnaires, as well as patients who were 
included despite not meeting the inclusion criteria 
and patients with no data regarding antihyperten-
sive treatment, we finally analysed data from 12,375 
patients [11]. 
All patients underwent standard clinical evalua-
tion. The known duration of the hypertension was 
recorded. Weight and height as well as waist cir-
cumference were measured. Body mass index (BMI) 
was calculated. Abdominal obesity was defined as 
a waist circumference > 102 cm and > 88 cm, for 
women and men respectively [2, 12]. Current an-
tihypertensive medications were also documented. 
Plasma sodium, potassium, glucose, creatinine and 
total cholesterol, low density lipoprotein (LDL) 
cholesterol, high density lipoprotein (HDL) cho-
lesterol and triglycerides concentration, history of 
coronary artery disease (CAD), previous myocardial 
infarction, heart failure, arrhythmias, cerebrovas-
cular diseases (CVD, including previous transient 
ischemic attack or stroke), asthma or chronic ob-
structive pulmonary disease (COPD), depression 
or anxiety, diabetes and other diseases were assessed. 
Each participating doctor was provided with speci-
fic instruction for these assessments. The estimated 
glomerular filtration rate (eGFR) was calculated 
according to the Modification of Diet in Renal Di-
sease (MDRD) study formula [13]. Cardiovascular 
risk (stratification into 4 groups: low, moderate, 
high and very high added risk) as well as metabolic 
syndrome were evaluated according to the criteria 
of the 2013 ESH/ESC guidelines [2]. 
BP was measured with a patient in the sitting po-
sition after a 5 min rest. Based on upper arm circum-
ference, an appropriately sized cuff was placed on the 
arm with the lower edge of the cuff 2 cm above the 
antecubital fossa. Three consecutive readings were 
performed. The average of these three readings was 
recorded. Each participating doctor was provided 
with detailed instruction for BP measurement. Use 
of devices with proofed accuracy was recommended. 
We defined hypertension control as BP levels both 
lower than 140 mm Hg for systolic and lower than 
90 mm Hg for diastolic blood pressure [2].
Data analysis was carried out using the statistical 
software PASW Statistics 18 (SPSS Inc., Chicago, IL, 
USA). The results are presented as mean ± one stan-
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dard deviation, or median and interquartile range. 
The values of variables were compared between 
groups — continuous and discrete variables: Stu-
dent’s t test, Mann-Whitney test or univariate ANO-
VA analysis with Duncan post-hoc test; categorical 
variables: chi2 test or Fisher exact test. Multivariate 
logistic regression models were performed, in order 
to determine the combined effect of several variables 
on the prevalence of the characteristic. For multi-
variate analysis the variables with significant asso-
ciation were included. Multicollinearity was checked 
by variation inflation factor. P < 0.05 was considered 
statistically significant.
Results
As described previously, we included 12,375 patients 
(mean age 64.0 ± 12.3 years; age range 18–98 years; 
59% females) [11]. Overall, 7080 patients (57.2% 
of the whole group) were treated with beta-blockers. 
Among 5 major classes of antihypertensive drugs 
beta-blockers were the second most frequently used 
antihypertensive group after angiotensin convert-
ing enzyme (ACE) inhibitors (61.3% of the whole 
group) and before thiazide/thiazide-type diuretics, 
calcium channel blockers and angiotensin II receptor 
blockers (ARBs) (respectively: 48.0%, 36.5% and 
35.3%). Among hypertensive patients on monothe-
rapy beta-blockers were the third most frequently 
used antihypertensive group after ACE inhibitors 
and ARBs (Figure 1).
Patients treated with beta-blockers were charac-
terized by higher: age, BMI, frequency of abdominal 
obesity, pulse pressure, median number of antihyper-
tensive drugs, plasma concentrations of triglycerides 
and glucose and lower concentrations of total and 
LDL cholesterol as well as by lower eGFR (Table 1). 
There were no differences between patients treated 
with beta-blockers and not treated with beta-blockers 
in systolic and diastolic BP level and in the rate of 
hypertension control as well as in plasma concen-
tration of sodium, potassium, HDL cholesterol, and 
creatinine (Table 1). 
We analysed the rate of use of beta-blockers in 
3 age categories (40 years and less, 40–65 years and 
65 years and more) (Figure 2). Overall, beta-blockers 
were used more frequently in the 40–65 years and 
65 and more years groups. Among patients on mono-
therapy there was no difference in the rate of use of 
beta-blockers among the three age groups. Among 
patients on 2 antihypertensive drugs beta-block-
ers in combination with renin-angiotensin blockers 
were used most frequently in the 40–65 years group. 
Among patients on 3 antihypertensive drugs, the com-
bination of a beta-blocker, a renin-angiotensin blocker 
and a thiazide/thiazide-type diuretic was used more 
frequently in the 40 years and less group and in the 
40–65 years group (Figure 2). Among age categories 
40–65 years and 65 years and more, beta-blockers 
were used more frequently in patients with high and 
very high cardiovascular risk than in patients with 
low and moderate cardiovascular risk. Among patients 
40 years and less, the rate of use of beta-blockers was 
not related to the cardiovascular risk level (Figure 3).
The rate of use of beta-blockers was higher in 
patients with metabolic syndrome, diabetes, coro-
nary artery disease, previous myocardial infarction, 
heart failure, arrhythmias, cerebrovascular disease 
and eGFR lower than 60 ml/min/1,73 m2 than 
in patients without those conditions (Figure 4). 
Beta-blockers were used less frequently among pa-
tients with asthma/COPD than without asthma/ 
/COPD (54.0 vs 58.0%; p = 0.017). Among pa-
tients with anxiety/depression, the rate of use of be-
ta-blockers was higher than among patients without 
anxiety/depression (62.1% vs 56.6%; p < 0.001).
Rate of specific conditions in which beta-blockers 
might be preferred: heart failure, previous myocar-
dial infarction (without heart failure), arrhythmias 
(excluding patients with heart failure and previous 
myocardial infarction) and coronary artery disease (ex-
cluding patients with heart failure, previous myocar-
dial infarction and arrhythmias) in all patients treated 
with beta-blockers and in patients treated with be-
Figure 1. Rate of use of antihypertensive drugs among patients 
on one antihypertensive drug. Data are presented as a number of 
patients and rate
ACEi — angiotensin converting enzyme inhibitor, ARB — angiotensin II receptor blocker, BB — beta-
-blocker, CCB — calcium channel blocker, n — number of patients, TD — thiazide/thiazide-type diuretic
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Table 1. Characteristics of patients treated or not with beta-blockers in the studied group
N Treated with beta-blocker Untreated with beta-blocker P
Number 12375 7080 5295
Gender (% of F) 12375 58.5 59.7 0.19
Age (years) 12375 64.9 ± 11.7 62.8 ± 12.9 < 0.001
BMI [kg/m2] 12094 29.3 ± 4.7 28.5 ± 4.5 < 0.001
Abdominal obesity (%) 12264 56.5 50.5 < 0.001
Systolic BP [mm Hg] 12375 140 ± 16 140 ± 15 0.29
Diastolic BP [mm Hg] 12375 84 ± 11 84 ± 13 0.087
Pulse pressure [mm Hg] 12375 56 ± 13 55 ± 15 0.011
Number of antihypertensive drugs (n) 12375 3 (2–4) 2 (1–3) < 0.001
Controlled HT (%) 12375 47.0 47.8 0.38
Sodium [mmol/L] 7230 140.1 ± 3.7 140.1 ± 3.9 0.41
Potassium [mmol/L] 7911 4.4 ± 0.4 4.4 ± 0.4 0.21
Creatinine concentration [µmol/L] 8669 90.5 ± 42.6 88.0 ± 33.9 0.18
eGFR [ml/min/1.73m2] 8708 72.4 ± 23.4 74.0 ± 23.9 0.002
Glucose [mmol/L] 10647 5.78 ± 1.38 5.58 ± 1.28 < 0.001
Total cholesterol [mmol/L] 9406 5.31 ± 1.11 5.45 ± 1.07 < 0.001
LDL cholesterol [mmol/L] 8710 3.14 ± 0.97 3.27 ± 0.93 < 0.001
HDL cholesterol [mmol/L] 8806 1.39 ± 0.77 1.42 ± 0.62 0.051
Triglycerides [mmol/L] 9734 1.68 ± 0.67 1.65 ± 0.63 0.012
The results are presented as mean ± one standard deviation or median and interquartile range in the parenthesis. Categorical variables are shown as frequencies. 1 — for comparison between 3 groups, 2 — for compa-
rison between patients with controlled and uncontrolled hypertension, 3 — for comparison between patients with controlled and resistant hypertension 
BMI — body mass index, BP — blood pressure, eGFR — estimated glomerular filtration rate, F — females, HDL — high density lipoprotein, HT — hypertension, LDL — low density lipoprotein, M — males
Figure 2. Rate of use of the beta-blockers (%) in all patient and in patient receiving monotherapy, rate of use of combination of angiotensin 
converting enzyme inhibitor or angiotensin II receptor blocker and beta-blocker (%) among patients receiving 2 antihypertensive drugs and 
rate of use of combination of angiotensin converting enzyme inhibitor or angiotensin II receptor blocker and beta-blocker and thiazide/thiazi-
de-type diuretic (%) among patients receiving 3 antihypertensive drugs across the age categories < 40 years, 40–65 years and ≥ 65 years
*, **, *** — p < 0.001 for the differences across the age categories < 40 years, 40–65 years and ≥ 65 years
ACEi — angiotensin converting enzyme inhibitor, ARB — angiotensin II receptor blocker, TD — thiazide/thiazide-type diuretic
arterial hypertension 2015, vol. 19, no. 3
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Figure 3. Rate of use of beta-blockers in relation to cardiovascular risk stratification in according to the 2013 ESH/ESC guidelines across the 
age categories < 40 years, 40–65 years and ≥ 65 years
ESH/ESC — European Society of Hypertension/European Society of Cardiology
Figure 4. Rate of use of the beta-blockers (%) in relation to coexisting clinical conditions in the studied group 
*P value for comparison between patients with and without coexisting clinical condition
eGFR — estimated glomerular filtration rate, HT — hypertension
ta-blockers across the age categories < 40 years, 40–65 
years and ≥ 65 years were evaluated (Figure 5). In all 
patients treated with beta-blockers the most frequent 
conditions were coronary artery disease and heart fail-
ure (Figure 5A). In patients aged 40 years and young-
er, those conditions were found only in 21.7% of 
patients (Figure 5B). In patients aged 40-65 years, the 
most frequent conditions were coronary artery disease 
and arrhythmias, however none of the listed above 
conditions was found in 41.3% of patients (Figure 
5C). In older patients treated with beta-blockers, the 
most frequent conditions were coronary artery disease, 
previous myocardial infarction and heart failure pre-
sent in 70.1% of patients (Figure 5D).
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Figure 5. Rate of specific conditions in which beta-blockers might be preferred: heart failure, previous myocardial infarction (without heart 
failure), arrhythmias (excluding patients with heart failure and previous myocardial infarction) and coronary artery disease (excluding patients 
with heart failure, previous myocardial infarction and arrhythmias) in all patients treated with beta-blockers (A) and in patients treated with 
beta-blockers across the age categories < 40 years (B), 40–65 years (C) and ≥65 years (D)
We performed multivariate models (including 
gender, age, pulse pressure, abdominal obesity, me-
tabolic syndrome, diabetes, coronary artery disease, 
previous myocardial infarction, heart failure and 
arrhythmias) to assess independent association of 
factors with the treatment with beta-blockers in the 
whole studied group and across the age categories 
< 40 years, 40–65 years and 65 years and more. 
Only abdominal obesity or metabolic syndrome and 
arrhythmias were independently associated with be-
ta-blockers use in the whole group and across all age 
categories (Table 2). Coronary artery disease and 
previous myocardial infarction were associated inde-
pendently with beta-blockers use in patients 40–65 
years and in patients 65 year and more. In the latter 
group also heart failure was independently associated 
with beta-blockers use.
Discussion
Beta-blockers have long been used as a first-line the-
rapy for hypertension because they were thought to 
have long-term favourable effects on all-cause and 
cardiovascular mortality, but the robustness of the 
evidence for initiating antihypertensive therapy with 
beta-blockers has been challenged [14]. Moreover 
as summarized by the ESH/ESC 2013 guidelines, 
none of the preferred 2 drugs combination is based 
on beta-blockers. Although the thiazide diuretic–be-
ta-blocker combination has been shown to be effec-
tive in cardiovascular risk reduction, this combina-
tion appears to elicit more cases of new-onset diabetes 
in susceptible individuals, compared with other combi-
nations. Therefore this combination has been described 
as “useful combination (with some limitations)” [2, 15]. 
However Polish Society of Hypertension 2015 guide-
lines listed two combinations containing a beta-blocker 
(with an ACE inhibitor or a calcium channel blocker) 
as preferred combinations [3]. 
Our study showed that despite those concerns 
the rate of use of beta-blockers in Poland remains 
relatively high (57.2%) and this group of antihyper-
tensive drugs remains one of the most often select-
ed antihypertensive medication classes used for the 
treatment of hypertension only second to renin-an-
arterial hypertension 2015, vol. 19, no. 3
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giotensin blockers (ACE inhibitors and ARBs). Be-
ta-blockers were used more frequently in polytherapy 
regimens than in monotherapy. The recent data from 
German Health Examination Surveys showed high 
rate of beta-blockers use, rising from 39% in 1998 
to 54% in 2008–2011 [7]. In the evaluation of the 
United States National Health and Nutrition Exa-
mination Survey (NHANES), the overall prevalence 
of use of beta-blockers increased from 20.3% in 
NHANES 2001 to 2002 to 31.9% in NHANES 
2009 to 2010 (the rates were given for all hyperten-
sive patients — both treated and untreated). This 
was mainly driven by a 65% increase in the use of 
beta-blockers used in polytherapy regimens to treat 
hypertension [10]. Also other studies showed similar 
trends for beta-blocker use in hypertensive patients 
[8, 9].
Beta-blockers are recommended when hyperten-
sion is associated with certain compelling co-mor-
bidities. In post-myocardial infarction setting, be-
ta-blockers decrease recurrent myocardial infarction 
and improve survival. They have been also shown to 
improve functional class, reduce frequency of hospi-
talization and improve survival in patients with heart 
failure [14]. In our studies those conditions were 
found in respectively 21% and 11% of patients on 
beta-blockers. Moreover, respectively 82% and 73% 
of patients with those conditions were taking be-
ta-blockers. Thus we showed high utilization of this 
group in conditions where benefits of beta-blocker 
are proven. Our results also underline that patients 
with hypertension are characterized by pronounced 
cardiovascular burden and frequent concomitant car-
diovascular disease requiring beta-blockers’ use.
Our study showed that the rate of use of be-
ta-blockers in patients with asthma/COPD was low-
er than in patients without these conditions. Histor-
ically, beta-blockers have sometimes been withheld 
from asthma or COPD patients. Taking into account 
that most of the patients in this group in our study 
had COPD, it should be noted that several studies 
including COPD and beta-blocker treatment found 
a protective effect of beta-blockers on all-cause mor-
tality both in primary or secondary prevention [16]. 
Thus emphasis should be placed on higher awareness 
of benefits of beta-blocker treatment in patients with 
COPD. Nevertheless, these agents should be used 
with caution in patients with pulmonary disease [14].
There is concern that beta-blockers may impair 
glycaemic control by reducing insulin sensitivity and 
mask hypoglycaemia. However, beta-blockers may 
produce greater improvements in cardiovascular out-
come among diabetic patients compared with those 
without diabetes. Treatment with third-generation 
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beta-blockers does not appear to be associated with 
changes in glycaemic control and may improve in-
sulin sensitivity [14, 17]. We found that the rates 
of use of beta-blockers were higher both in patients 
with diabetes or metabolic syndrome as compared 
with patients without those symptoms. Although 
we were not able to differentiate which particular 
agents were used, current guidelines advise that ad-
ditional receptor mediated effects (alpha1-adrenergic 
receptor blockade by carvedilol, beta3-adrenergic re-
ceptor activation by nebivolol), beneficial effects on 
metabolic parameters and endothelial function, and 
the results of large-scale clinical trials all suggest that 
vasodilating beta-blockers should be preferred if a be-
ta-blocker is indicated in hypertensives with diabetes 
or metabolic syndrome [3].
Beta-blockers are the drugs of first choice for the 
treatment of hypertension in patients with coronary 
artery disease that causes angina [18]. However, no 
large trails have been performed to assess their effec-
tiveness in reducing major cardiac events in patients 
with stable coronary disease without prior myocar-
dial infarction. In a large study based on evaluation 
of electronic health records, it has been shown that 
use of beta-blockers among patients with new-onset 
coronary artery disease was associated with lower risk 
of cardiac events only among patients with a recent 
myocardial infarction [19]. Also in the post hoc ana-
lysis from the Clopidogrel for High Atherothrom-
botic Risk and Ischaemic Stabilization, Management, 
and Avoidance (CHARISMA) trial showed that be-
ta-blocker use is not associated with lower cardio-
vascular events in those with coronary artery disease 
without prior myocardial infarction, with suggestion 
of inferior outcome with regard to stroke risk [20]. 
However, these findings have not been conferred in 
the guidelines [1–3]. In our study, stable coronary 
artery disease without prior myocardial infarction 
was the most frequent compelling indication for the 
utilization of beta-blockers. This finding in the light 
of uncertain cardioprotective effect emphasize the 
need of further studies aimed on evaluation of these 
agents benefits in patients with stable coronary artery 
disease without prior myocardial infarction.
The anti-arrhythmic properties result from de-
creased sympathetic and heart rate activity and in-
creased cardiac vagal tone. According to current guide-
lines, use of beta-blockers in the treatment of hyper-
tension is recommended in patients with arrhythmias 
[2, 3, 14]. Our study showed high utilization of these 
agents in patients with arrhythmia as well as that ar-
rhythmias remain a compelling indication for use of 
these agents in hypertensive subjects, especially young-
er than 40 years and in the age group of 40–65 years.
The use of beta-blockers remains the subject of 
debate. They are no more effective than other antihy-
pertensive agents and, according to some recent ana - 
lysis, they failed to reduce myocardial infarction 
while providing less protection against strokes. This is 
particularly true for atenolol [21–23]. Nevertheless, 
the current Polish Society of Hypertension guidelines 
upheld the position taken in the previous guidelines 
that beta-blockers should remained among first-line 
antihypertensive drugs, stressing that that vasodilat-
ing agents (carvedilol, nebivolol) due to their haemo-
dynamic properties (smaller negative chronotropic 
effect and a reduction of total peripheral resistance), 
resulting in a more favourable effect on central aor-
tic pressure, should be preferred among beta-blockers 
in patients with uncomplicated hypertension. This 
has been also reflected in the text of the 2013 ESH/ 
/ESC guidelines that noted some beneficial aspects of 
the mechanism of action of vasodilating beta-blockers 
[1–3]. Our study showed high rate of patients on 
beta-blockers with none of the compelling indications 
discussed above in younger patient but not in older 
patients (especially those over 65 years). In patients 
older than 40 years use of beta-blockers was related to 
the level of cardiovascular risk it was not true for pa-
tients younger than 40 in whom no relation between 
level of cardiovascular risk and utilization of these 
agents was found. Although we were not able to assess 
the particular drugs used, more emphasis should be 
put on the use of vasodilating beta-blockers in younger 
patients in whom beta-blockers are frequently used 
with none of the compelling indications present.
Conclusions
Our study based on a large group of treated hyper-
tensive patients has shown high utilization rate of 
beta-blockers in patients with hypertension, only 
second to renin-angiotensin blockers. In middle age 
and, especially, in older patients it might reflect high 
cardiovascular burden of those patients, including 
coexistence of established cardiac disease. In younger 
patients beta-blockers are used more frequently with 
none of the compelling indications present.
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